Excellent #MCS conference before AHA for #HF and transplant faculty, fellows and allied healthcare providers interested in an one-day comprehensive course on #LVAD, #CS and #TCS. Register 👇

Time to consider a trial of temporary RVADs in #HF patients high-risk for RVF going for #LVAD implant. Is this the right tool or should we be thinking about AI of RV function on ECHO or dare I say RVF risk score? Jeff Teuteberg @manreetkanwar Rebecca Cogswell Susan Joseph MD

Clinical and translational reviews in myocardial recovery with #MCS for physicians and scientists. A step by step guide to help realize recovery in your #LVAD / #HF patients. Jennifer Cowger Rebecca Cogswell Jane Wilcox, MD, MSc The ISHLT Jeff Teuteberg Anju Bhardwaj MD FACC Ravi Karra Finn Gustafsson

Super fun debates in #cardiogenicshock ongoing HFSA. Shock team v. No teams, RCTs v. No RCTs. Jennifer Cowger @manreetkanwar Vanessa Blumer, MD, FACC David Baran Rachna Kataria, MD Lauren Cooper Jason N. Katz

The ⁦⁦@IHVInews⁩ HF/MCSTXP team celebrating our OneTeam ⁦HFSA⁩ 2022. ⁦Mitchell Psotka⁩ ⁦Carolyn Rosner⁩ ⁦Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA⁩ ⁦Behnam N. Tehrani, MD⁩ ⁦Lauren Cooper⁩ ⁦Iyad Isseh إياد نبيل العسّة⁩

Congrats to the chairs of the The ISHLT #MCS core academy on a wonderful program and packed audience. Dynamic session with excellent participant engagement. Even the teachers learned! Now off to #AHA2022. Stavros George Drakos Jennifer Cowger @manreetkanwar Farooq Sheikh Rebecca Cogswell

Newly published guidelines on care of the #hearttransplant patient from the The ISHLT in @JHLT: jhltonline.org/article/S1053-…

In depth review within Circulation that provides comprehensive guidance for clinicians and scientists on assessment of #DSA, #cellfreeDNA and highlights disparities in care amongst Black #hearttransplant patients. Dr. Agbor-Enoh Omics Lab Jason F. Goldberg MD MS Josef Stehlik Shelley Hall

#Tweetorial (1 of 6) dd-cfDNA has significant evidence in diagnosing ACR and AMR. GEP can diagnose ACR only, and HLA antibodies are associated with AMR. More data needed for MicroRNA and Proteomics and in CAV. Palak Shah Lauren K. Truby Annette Jackson Kiran Khush Dr. Agbor-Enoh Omics Lab

Withdrawal of aspirin is safe in #LVAD patients, how about apixaban instead of warfarin? Introducing the DOAC LVAD Study—design paper online NOW Journal of Cardiac Failure 👇 #ARIES #DOAC #LVAD Palak Shah Mary Looby Christopher O'Connor @IHVInews doi.org/10.1016/j.card…

Fantastic Inova @IHVInews show at #AHA2023 Palak Shah Garima Sharma M.D Christopher O'Connor Christopher DeFilipp Vanessa Blumer, MD, FACC

Inova & George Mason University are seeking a post-doctoral research fellow in Advanced Heart Failure. Great opportunity for those looking to accelerate their academic careers. Vanessa Blumer, MD, FACC Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA Jason F. Goldberg MD MS Mitchell Psotka Inova Schar Heart and Vascular The ISHLT Iyad Isseh إياد نبيل العسّة Abdulla A. Damluji, MD, PhD

⁦Palak Shah⁩ shares #LBCT results #DOAC #LVAD pilot study #THT2024 Time now 4 pivotal RCT on anticoagulation in durable #MCS? ⁦Christopher O'Connor⁩ ⁦Mitchell Psotka⁩ ⁦Iyad Isseh إياد نبيل العسّة⁩ ⁦Mary Looby⁩ ⁦Inova Schar Heart and Vascular⁩ ⁦Inova⁩ ⁦InovaCVfellows⁩

Result of Inova Schar Heart and Vascular study of DOAC in patients with advanced HF with LVAD -- presented at Cardiovascular Research Foundation #THT by Palak Shah and discussed in TCTMD tctmd.com/news/small-stu…

Palak Shah, M.D. + Inova Schar Heart and Vascular will receive a $1.4M grant to develop a blood test to optimize care for pediatric heart transplant patients. This research could help kids w/ new hearts live longer lives. 👏 Inova, Christopher O'Connor, Palak Shah #BoldHearts spr.ly/6018b5Ebj

Great cardiac biomarker meeting in beautiful La Jolla. A must for those interested in CV biomarkers in CAD and HF. Inova Schar Heart and Vascular

Excited to start the OPTIMA study with 5 pediatric heart transplant centers across the US. Working on developing novel biomarkers to optimize immunosuppression after transplant. Inova Schar Heart and Vascular Jason F. Goldberg MD MS PHTSociety

Congratulations Shashank a special opportunity for a distinguished physician scientist with a bright future ahead! I’m sure there were so many pearls of wisdom shared. A true presidential privilege.

This initial study with apixaban demonstrates feasibility of using this medication in #LVAD patients. We look forward to working with the #MCS community on a phase 3, multicenter RCT to demonstrate safety and efficacy of this treatment.